Q1 EPS Estimate for U.S. Physical Therapy Lowered by Analyst

U.S. Physical Therapy, Inc. (NYSE:USPH) – Analysts at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for shares of U.S. Physical Therapy in a research note issued to investors on Thursday, February 27th. William Blair analyst J. Haase now expects that the company will earn $0.56 per share for the quarter, down from their previous forecast of $0.59. William Blair has a “Market Perform” rating on the stock. The consensus estimate for U.S. Physical Therapy’s current full-year earnings is $2.67 per share. William Blair also issued estimates for U.S. Physical Therapy’s Q1 2025 earnings at $0.56 EPS, Q2 2025 earnings at $0.79 EPS, Q2 2025 earnings at $0.79 EPS, Q4 2025 earnings at $0.78 EPS, Q4 2025 earnings at $0.78 EPS, FY2025 earnings at $2.96 EPS and FY2025 earnings at $2.96 EPS.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.04). U.S. Physical Therapy had a return on equity of 8.11% and a net margin of 3.54%. The business had revenue of $180.45 million during the quarter, compared to the consensus estimate of $173.10 million.

Several other research analysts also recently weighed in on the company. StockNews.com downgraded U.S. Physical Therapy from a “hold” rating to a “sell” rating in a research note on Friday. Citizens Jmp upgraded U.S. Physical Therapy to a “strong-buy” rating in a research report on Monday, December 16th. JPMorgan Chase & Co. increased their target price on U.S. Physical Therapy from $117.00 to $120.00 and gave the company an “overweight” rating in a research report on Tuesday, December 3rd. Bank of America upgraded U.S. Physical Therapy from a “neutral” rating to a “buy” rating and increased their target price for the company from $100.00 to $115.00 in a research report on Monday, December 16th. Finally, JMP Securities initiated coverage on U.S. Physical Therapy in a research report on Monday, December 16th. They set an “outperform” rating and a $113.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $111.50.

U.S. Physical Therapy Trading Down 1.6 %

USPH stock opened at $81.08 on Friday. U.S. Physical Therapy has a 1-year low of $76.18 and a 1-year high of $113.63. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.78. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 86.26, a PEG ratio of 3.54 and a beta of 1.48. The business has a 50 day simple moving average of $88.41 and a two-hundred day simple moving average of $87.67.

Institutional Trading of U.S. Physical Therapy

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CBIZ Investment Advisory Services LLC raised its holdings in U.S. Physical Therapy by 59.8% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 326 shares of the company’s stock valued at $29,000 after buying an additional 122 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in U.S. Physical Therapy in the fourth quarter worth $39,000. Venturi Wealth Management LLC increased its stake in U.S. Physical Therapy by 3,200.0% in the fourth quarter. Venturi Wealth Management LLC now owns 726 shares of the company’s stock worth $64,000 after purchasing an additional 704 shares during the period. KBC Group NV increased its stake in U.S. Physical Therapy by 68.6% in the third quarter. KBC Group NV now owns 774 shares of the company’s stock worth $66,000 after purchasing an additional 315 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in U.S. Physical Therapy in the fourth quarter worth $84,000.

Insider Activity at U.S. Physical Therapy

In related news, CFO Carey P. Hendrickson sold 516 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $96.25, for a total transaction of $49,665.00. Following the sale, the chief financial officer now owns 20,469 shares in the company, valued at approximately $1,970,141.25. This represents a 2.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.70% of the stock is currently owned by insiders.

U.S. Physical Therapy Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 11th. Investors of record on Friday, March 14th will be issued a dividend of $0.45 per share. The ex-dividend date is Friday, March 14th. This represents a $1.80 annualized dividend and a yield of 2.22%. U.S. Physical Therapy’s payout ratio is presently 95.65%.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.